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Abstract 
Background. Pancreatic encephalopathy is a rare complication of severe acute pancreatitis, with high 
mortality, being difficult to diagnose and treat, thus requiring continuous research regarding its 
management. 
Materials and Methods.  Of  20 patients diagnosed with severe acute pancreatitis on admission at 
Department  of  Emergency and Admission (DEA), from January 1st 2010 to March 31st 2014, 5 cases 
complicated by pancreatic encephalopathy were analyzed using a descriptive observational, 
retrospective, single-centre study. 
Results. The study shows different types of diagnostic algorithm and therapeutical approaches, in 
correlation with morbidity and mortality rates. 
Conclusions. Our study highlighted the fact that speed is critical, early management being the key to 
outcome. 
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Introduction 
Pancreatic encephalopathy, un uncommon complication of severe acute pancreatitis, was first 
described in 1941 by Rothermich and Von Haam and later by Vogel (1, 2). Neurological signs and 
symptoms may occur in the first two weeks of acute pancreatitis, irrespective of the etiology. It can 
have an acute onset, with convulsions, amaurosis, paresis, dysarthria, or it can have a progressive 
onset with beahvioural changes, psychomotor agitation, space and time dysorientation, visual or 
auditory hallucinations, affected consciousness that can lead to coma. These sympoms can have a 
cyclic evolution, with repeated relapses and remission. 
As a complication of gallstone SAP, pancreatic encephalopathy (PE) is difficult to diagnose and 
treat, with a high mortality rate and poor prognosis. The onset of pancreatic encepalopathy in the 
early stage was regarded as a poor prognosis sign of severe acute pancreatitis (SAP), the pathogenesis 
still not being fully clarified. The development of PE in SAP may be a multi-factor process. Finding 
out the possible inducing factor represents an essential step for the management of PE in SAP. 
For an accurate assessment of the severity of acute pancreatitis, several systems for classifying 
disease severity have been proposed, assisting in selection of patients (admission to a medical ward or 
to an intensive care unit) and also being applied at diagnosis in association with repeated clinical 
assessment, measurement of acute inflammatory markers, and computer tomography imaging. These 
include the Ranson criteria, Glasgow scales, Simplified Acute Physiology score and Acute 
Physiology And Chronic Health Evaluation II (APACHE II) score and the clinical BISAP score. The 
CT Severity Index (CTSI) derived by Balthazar grading of pancreatitis and the extent of pancreatic 
necrosis is largely used in describing CT findings of acute pancreatitis and serves as the radiological 
scoring system (3). 
The etiology and pathogenesis have been continually investigated for centuries worldwide, 
being initiated by several factors, including gallstones, alcohol, trauma, infections and hereditary 
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factors. Acute biliary pancreatitis (ABP) is a potentially fatal disease caused by gallstones and 
represents approximately 35% to 70% of cases with pancreatitis worldwide (4). Several studies, 
however, reported a wider range, from 10% to 70% (5).  
This article reviews these topics with a focus on surgical management, including appropriate 
timing and choice of interventions, the aim of the present study being to review the current 
management of gallstone pancreatitis, in cases developing PE, in “St. Pantelimon” Emergency 
Clinical Hospital, Bucharest, and to determine the extent to which the management is compliant with 
recently published consensus guidelines. 
 
Materials and Methods 
A descriptive observational, retrospective, single-centre study was carried out through the 
analysis of the medical records of consecutive patients admitted at the General Surgery Department of 
the “St. Pantelimon” Emergency Clinical Hospital, an academic hospital of the University of 
Medicine and Pharmacy “Carol Davila” in Bucharest, Romania, from January 1st 2010 to March 31st 
2014 with a diagnosis of acute pancreatitis on admission at Department of Emergency and Admission 
(DEA).  
Patients were treated, as well as written or oral informed consents for each procedure adopted 
were collected, according to the usual clinical practice.  
Database and Study population 
ICD-10 CM codes were used to identify cases of pancreatitis, biliary disease and 
encephalopathy. Inclusion criteria were: age ≥18 years; presence of recent neurological signs and/or 
dementia, diagnosis of severe acute biliary pancreatitis (any of the following three definitions: 
gallstones and/or sludge diagnosed on imaging (transabdominal or endoscopic ultrasound or 
computed tomography); in the absence of gallstones and/or sludge, a dilated common bile duct on 
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ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old); and alanine 
aminotransferase level >2 times higher than normal values, with serum alanine aminotransferase 
levels >aspartate aminotransferase level) and written informed consent (6, 7). Exclusion criteria were:  
patients with ongoing alcohol abuse or chronic pancreatitis, or pregnancy.  
Data were recorded regarding demographics, diagnosis, predicted and actual severity of 
gallstone pancreatitis (index and recurrent attacks), the role of computed tomography and magnetic 
resonance scanning, the timing of cholecystectomy (open and laparoscopic), intraoperative 
cholangiography, duration of hospital stay, complications and mortality. 
Statistics  
The analysis of the data was made by means of descriptive statistical methods, using EpiInfo, a 
free software created by Centers for Disease Control and Prevention, Atlanta, USA and the Microsoft 
Office Excel software. Probabilities less than 0.05 were accepted as significant. 
 
Results 
In the aforementioned period 43 patients with final diagnosis of acute pancreatitis were 
identified, almost 60% (25 patients) presenting acute biliary pancreatitis, with 20 cases of severe 
disease, according to APACHE II and BISAP scoring systems, 5 of them being diagnosed with 
pancreatic encephalopathy. 
At its most basic, severe acute pancreatitis is defined by organ failure lasting for more than 48 
hours, according to modified Marshall scoring system, half of the study patients presenting clinically 
significant organ insufficiency, requiring urgent contrast enhanced CT for determination of the local 
extent of necrosis or local complications. 
The degrees of severity (mild, moderately severe and severe) are also based on the presence or 
absence of local and systemic complications.  
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The local complications that occurred in the study population were: acute peripancreatic fluid 
collections in 2 cases, pancreatic pseudocysts in 3 cases, acute necrotic collections and walled-off 
necrosis in 5 cases, with 2 cases developing infected pancreatic necrosis, and biliary obstruction for 6 
patients. 
Renal, circulatory, or respiratory organ failure, or exacerbation of serious preexisting 
comorbidities related directly to acute pancreatitis are examples of systemic complications of acute 
pancreatitis with associated SIRS.  
Pancreatic encephalopathy occured 4 hours to the 35th day after the onset of SAP: 1 patient 
within the first 24 hours, 1 case within 24 to 72 hours, 2 patients developed the complication in the 72 
hours- 20 days interval and 1 case was diagnosed with PE after 20 days. The clinical symptoms were 
excitement (hallucination, fidget and handicaped directions), in 3 cases, and restrain (indifference, 
temporospatial dysorientation, coma), in 2 cases. Two patients showed modifications to some extent 
on electroencephalogram, the other 3 not being checked electroencephalographically. PE was the only 
complication in 1 case, and in the other 4 cases, local or systemic complications, such as pancreatic 
pseudocysts, acute necrotic collections or multiple organ failure were also present.  
Three of the patients with PE had developed the neurologic dysfunction in the first 2 weeks 
after the onset of the SAP, with the remission of the symptomatology after treatment of the SAP. 
In the present study 2 patients developed PE 
late in the evolution of the SAP, receiving 
intravenous vitamine B1 treatment, alleviating the 
symptomatology (Figure 1). 
The comorbid conditions existing in the 
study population were cardiovascular            
Figure 1. Time of the onset of the PE     in 3 cases, respiratory in 3 cases, 2 patients 
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 with renal comorbidity, 3 with hepatic comorbidity, 2 patients with diabetes and 1 with cancer, all 5 
patients with PE presenting comorbidities (figure 2). Three patients suffered from multi-organ 
dysfunction syndrome and 2 patients developed abdominal compartment syndrome, with a sustained 
intra-abdominal pressure of more than 20 mm Hg. 
 The management for PE in ABP included life-support measures (including total parenteral 
nutrition [TPN], supply of vitamin B1, hemodialysis, mechanical ventilation [MV]), cholecystectomy, 
debridement of necrosis and minimally invasive 
(laparoscopic) approach to pancreatic necrosis. 
The simple and important first steps in the 
management of severe biliary acute pancreatitis, 
thus preventing PE, are provision    of adequate 
analgesia, efficient restoration of hypovolemia and 
        Figure 2. The frequency of comorbidities        correction of hypoxaemia. 
                   among the patient with PE. 
All patients, except those with cardiovascular, renal or other comorbidities who required 
caution, had undergone early adequate volume resuscitation, using less than 4 L of lactated Ringer’s 
solution (approximately 5-10 mL/kg per hour) in the first 24 hours, the optimum resuscitation being 
clinically evaluated by heart rate (<120bpm), mean arterial pressure (68-85 mmHg), urinary output 
(>1mL/kg per hour) and haematocrit (35-44%). 
Antibiotics, such as quinolones, metronidazole and high-dose cephalosporins, were used in 
2,out of the 5 patients with PE, with infected pancreatic necrosis, and 3, with extrapancreatic infection 
(urinary tract infection, pneumonia, catheter-acquired infection), who failed to improve after 7-10 
days of hospitalization. 
Total parenteral nutrition was considered in all 5 cases diagnosed with PE in SAP. In patients 
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with severe acute pancreatitis who deveoped PE, especially those with pancreatic necrosis, the 
cholecystectomy was delayed until a later time in the typically prolonged hospitalization in 4 cases, or 
after discharge, in 1 case. 
Minimally invasive debridement after 4 weeks of hospitalization by laparoscopic approach was 
done in all 3 cases of walled-off necrosis, 2 of them requiring open surgery at a later time. 
To characterize the impact of pancreatic encephalopathy in acute pancreatitis on the number of 
days of hospitalization, the analyses were made by stratifying the hospital stay into 2categories, by 
weeks of stay: 3 and greater than 3 weeks. The 
majority of the study population had a greater than 
3 weeks hospitalization (4 patients-80%), 1 
patients (20%) requiring 3 weeks hospitalization 
(figure 3). Within the 4 year study period, the 
mortality rate for the patients monitored has been 
Figure 3. The distribution of study population          calculated at 30% (6 cases of acute pancreatitis), 
according to the number of days hospitalization   with death occuring in 2 out of 5 patients with 
                                                                          pancreatic encephalopathy (40%). 
Discussion 
Pancreatic encephalopathy, as a syndrome of nervous and mental dysfunction secondary to 
metabolic abnormalities in severe acute pancreatitis, was first reported by Rothermich in 1941 (1). 
According to medical literature (8),  PE was classified into PE in early stage and late stage of 
SAP. In the early stage of SAP (the first 2 weeks), PE develops as a part of the multiple organ failure 
complication.  
20%
80%
Number of days of 
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In the acute phase, pancreatic enzymes, such as trypsin, phospholipase A, chymotrypsin, lead to 
cerebrovascular changes ( haemorrhage, nerve cell toxicosis, local encephalomalacia). A2 
phospholipase is activated by trypsin and bile acids, converting pancreatic lecithin and cephalin into 
hemolytic lecithin and cephalin, with a strong toxicity, being capable of destroying membrane 
phospholipids of the blood-brain barrier, thus resulting in cerebral haemorrhage, encephalomalacia 
and demyelinization. Also, A2 phospholipase can hydrolyze the mithocondrial enzymes, blocking the 
oxygenation at a cellular level. (Goke B, Meyer T, Loth H. Caracterization of phospholipase A2 
activity in aspirates of human pancreatic pseudocysts after isolation by reversed-phase high 
performance liquid cromatography (9). 
Other important elements involved in the complicated evolution of SAP are cell factors, such as 
cytokines, tumor-necrosis factor α (TNF α), 1β- interleukin (IL-1β), IL-6 and IL-10 (10-14). Also, 
SAP complications, such as respiratory insufficiency and hypooxygenemia, can cause abnormal 
metabolism and cerebral edema.  
The signs and symptoms are nonspecific and similar to those of other metabolic 
encephalopathies, making the diagnosis of pancreatic encephalopathy difficult. Among the 5 patients 
with PE included in the study, 3 had developed the neurologic dysfunction in the first 2 weeks after 
the onset of the SAP, all 3 having the symptomatology remitted after the treatment of the SAP. 
In the late stages of SAP, PE occured after 2 weeks of evolution or during convalescence, one 
of the factors involved in the ethiopathonegesis being represented by inadequate vitamine B1seric 
levels or intake. In the present study 2 patients developed PE late in the evolution of the SAP and 
received intravenous vitamine B1 treatment, allievating the symptomatology. 
Acute biliary pancreatitis is the result of a transient obstruction of the bile and pancreatic ducts, 
causing reflux of bile and duodenal content and/or increase of hydrostatic pressure in the pancreatic 
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duct (15).The severity of the disease is determined by the extent and the intensity of the local and 
systemic inflammatory reaction. According to animal models and human studies, the duration of 
obstruction is a critical factor determining the severity, with pancreatic necrosis developing more 
often when the obstruction exceeds 48 hours (16, 17). 
Due to the fact that Ranson score and modified Glasgow score have important limitations, 
containing data not routinely collected at the time of hospitalization and requiring 48 hours to 
complete, missing a potentially valuable early therapeutic window, the following scoring systems 
have been assigned to all the patients included in the study, in order to define severe pancreatitis: the 
APACHE II scoring system, the five-variables Bedside Index for Severity of Pancreatitis (BISAP) 
clinical scoring system, which predicts the in-hospital mortality (18), the presence of substantial 
pancreatic necrosis (>30% glandular necrosis on contrast enhanced CT), associated comorbidities and 
organ failure (Marshall scoring system). 
Speed is critical, early management being the key to outcome. All patients, including the study 
cases with pancreatic encephalopathy, except those with cardiovascular, renal or other comorbidities, 
who required caution, had undergone early adequate volume resuscitation, the cornerstone of early 
management, thus reducing the rates of organ failure, morbidity and mortality, as demonstrated in 
Warndorf et al retrospective study of patients with acute pancreatitis (19).  
The role of antibiotics in patients with severe ABP is to treat established infected necrosis, 
rather than prevent it, as demonstrated by Garg et al. (20), in accordance with the results of our study. 
The present study has shown that patients provided oral feeding, early in the course of ABP, 
had a shorter hospital stay, decreased infectious complications, decreased morbidity and decreased 
mortality, this being, also, demonstrated by other authors (21). In patients with  
severe acute pancreatitis, especially those with pancreatic encephalopathy , the cholecystectomy and 
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minimally invasive debridement was delayed until a later time in the typically prolonged 
hospitalization or after discharge (22, 23).  
 
Conclusions 
Identification of patients at risk for developing PE early in the course of acute pancreatitis is an 
important step in improving the outcome. Early aggressive hydration should be provided to all patients, 
unless cardiovascular, renal or other related comorbid factors exist. 
In severe AP, with PE, enteral nutrition is recommended. Parenteral nutrition should be 
avoided, unless the enteral route is not available, not tolerated, or not meeting caloric requirements. 
 For patients with severe ABP and PE, in order to prevent infection, cholecystectomy is to be 
deferred until neurological status improves, active inflammation subsides and fluid collections resolve 
or stabilize. 
Although unstable patients with infected necrosis should undergo urgent debridement, current 
consensus is that the initial management of infected necrosis for patients who are clinically stable 
should be a course of antibiotics before intervention to allow the inflammatory reaction to become 
better organized. 
The management for PE in ABP is represented by life-support measures, cholecystectomy, 
debridement of necrosis and minimally invasive (laparoscopic) approach to pancreatic necrosis. 
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